Edition:
United States

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

64.60USD
17 Oct 2017
Change (% chg)

-- (--)
Prev Close
$64.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
184,441
52-wk High
$66.00
52-wk Low
$32.05

Latest Key Developments (Source: Significant Developments)

Aerie Pharmaceuticals says ‍FDA committee to review NDA for Rhopressa
Friday, 13 Oct 2017 07:05am EDT 

Oct 13 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals Inc - ‍FDA advisory committee to review new drug application for Rhopressa (netarsudil ophthalmic solution) 0.02 pct​.  Full Article

Aerie Pharmaceuticals announces drug delivery asset acquisition
Thursday, 5 Oct 2017 06:00am EDT 

Oct 5 (Reuters) - Aerie Pharmaceuticals Inc : :Aerie Pharmaceuticals announces drug delivery asset acquisition to further advance its retinal disease program.Aerie Pharmaceuticals Inc - has acquired from Envisia Therapeutics Inc rights to use print technology in ophthalmology and certain other assets.Aerie Pharmaceuticals Inc - ‍Envisia will receive an initial $25 million in form of a combination of cash and Aerie common stock​.Aerie Pharmaceuticals Inc - expect to initiate ‍clinical trials for AR-13154 within next 18 to 24 months​.Aerie Pharmaceuticals Inc - ‍in addition, Aerie acquired Envisia's intellectual property rights relating to ENV1105​.  Full Article

Aerie Pharmaceuticals comments on notification from contract manufacturer
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals Inc - ‍received notification by its contract drug product manufacturer that contract manufacturer received CRL from U.S FDA.Aerie Pharmaceuticals - ‍CRL from FDA regarding contract manufacturer's NDA for one of their own product candidates manufactured at Tampa, Florida facility​.Aerie Pharmaceuticals Inc - ‍according to contract manufacturer, CRL refers to a Current Good Manufacturing Practice (CGMP) inspection at facility​.Aerie Pharmaceuticals Inc - ‍contract manufacturer has stated that they will work closely with FDA to determine appropriate next steps​.Aerie Pharmaceuticals Inc - ‍currently believe it is probable that open issues will be resolved prior to February 28, 2018 PDUFA date for Rhopressa​.  Full Article

Aerie Pharmaceuticals Q2 adj loss $0.63/shr
Tuesday, 1 Aug 2017 04:01pm EDT 

Aug 1 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals reports second quarter 2017 financial results and provides business update.Q2 adjusted loss per share $0.63.Q2 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.Q2 GAAP loss per share $0.82.  Full Article

Aerie Pharmaceuticals enters into collaboration agreement with DSM
Monday, 31 Jul 2017 06:30am EDT 

July 31 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals enters into collaboration agreement with DSM focused on technology to potentially deliver Aerie compounds to treat retinal diseases such as wet AMD.Aerie Pharmaceuticals-terms of agreement with DSM were not disclosed and agreement is immaterial to Aerie based on level of current financial commitments.  Full Article

Aerie Pharmaceuticals reports positive Roclatan phase 3 12-month topline safety results
Wednesday, 19 Jul 2017 04:01pm EDT 

July 19 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals reports positive roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% phase 3 12-month topline safety results.Aerie Pharmaceuticals Inc - ‍roclatan successfully demonstrates a positive safety profile and efficacy levels consistent with previously reported results​.Says ‍continue to expect to submit our roclatan™ NDA (new drug application) in first half of 2018​.  Full Article

Brian Grossman reports 6.3 pct passive stake in Aerie Pharmaceuticals Inc as of July 5 - SEC filing
Monday, 17 Jul 2017 04:52pm EDT 

July 17 (Reuters) - Aerie Pharmaceuticals Inc :Brian Grossman reports 6.3 percent passive stake in Aerie Pharmaceuticals Inc as of July 5 - SEC filing.  Full Article

Aerie Pharmaceuticals raises $125 mln
Friday, 26 May 2017 06:30am EDT 

May 26 (Reuters) - Aerie Pharmaceuticals Inc ::Aerie Pharmaceuticals raises $125 million in ATM sales and upsized follow-on offering.Aerie Pharmaceuticals -priced registered underwritten public offering of $75 million of shares of its common stock at a price to public of $53.75 per share.Aerie Pharmaceuticals-to use proceeds to fund expansion of commercialization programs in north america for rhopressa, roclatan, among others.Aerie Pharmaceuticals- $125 million is in addition to $50 million of shares sold through completion with Cantor Fitzgerald & Co.  Full Article

Aerie Pharma to offer common shares in public offering
Thursday, 25 May 2017 04:02pm EDT 

May 25 (Reuters) - Aerie Pharmaceuticals Inc :Aerie pharmaceuticals announces public offering of common stock.Aerie pharmaceuticals inc - commenced a registered underwritten public offering of $50 million of shares of its common stock.Aerie pharmaceuticals-to use proceeds of offering to fund expansion of its commercialization programs in north america for both rhopressa and roclatan.  Full Article

Aerie Pharmaceuticals announces FDA acceptance of NDA submission for Rhopressa
Monday, 15 May 2017 06:30am EDT 

May 15 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals announces fda acceptance of nda submission for Rhopressa(netarsudil ophthalmic solution) 0.02%.Aerie Pharmaceuticals Inc says receives notification from FDA of PDUFA date for Rhopressa.Aerie Pharmaceuticals Inc- PDUFA goal date for completion of FDA's review of Rhopressa NDA is set for february 28, 2018.Aerie Pharmaceuticals Inc - FDA is currently planning to hold an advisory committe.  Full Article

BRIEF-Aerie Pharmaceuticals announces FDA advisory committee vote in favor of Rhopressa

* Aerie Pharmaceuticals announces FDA advisory committee vote in favor of Rhopressa (netarsudil ophthalmic solution) 0.02%